First SARS-CoV-2 Infection in Patients with Severe Asthma Receiving Mepolizumab

Atayık, Emel; Aytekin, Gökhan

doi:10.5505/respircase.2021.43650

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to our patient, several cases have been reported of patients with a history of uncontrolled asthma who had been receiving mepolizumab before SARS-CoV-2 infection [ 29 , 35 ]. Aksu et al reported a case of a 55-year-old woman who had been hospitalized several times because of severe asthma but who recovered well despite COVID-19 [ 29 ].…”

Section: Discussionsupporting

confidence: 86%

“…Aksu et al reported a case of a 55-year-old woman who had been hospitalized several times because of severe asthma but who recovered well despite COVID-19 [ 29 ]. Additionally, a 61-year-old man with hypertension and a 20-year history of eosinophilic asthma who was receiving monthly injection of mepolizumab contracted COVID-19 and recovered without complications [ 35 ]. However, unlike our patient, the patients in both of these reported cases [ 29 , 35 ] were treated with favipiravir, an antiviral which has been shown to improve clinical outcomes in COVID-19 patients [ 36 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Mepolizumab as a Potential Protective Factor of COVID-19 Mortality: A Case Report of Chronic Bronchitis and Asthma in an Elderly Patient

et al. 2022

View full text Add to dashboard Cite

Unusual clinical course Background:Patients with multiple comorbidities who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have a higher risk of mortality. However, treatment with mepolizumab may be a key factor in counteracting the risk of these comorbidities. We present a patient who had an uneventful recovery from coronavirus disease 2019 (COVID-19), despite having 5 independent risk factors for severe disease and increased mortality. Case Report:A 75-year-old man with a long-standing history of asthma, chronic bronchitis, coronary artery disease, and hypertension presented to the Emergency Department in November 2020 with a 4-day history of fever, chills, shortness of breath, cough, and fatigue. Six months prior to this presentation, the patient was hospitalized for severe chronic bronchitis and acute exacerbation of asthma. His medications included mepolizumab, aclidinium, ramipril, diltiazem, aspirin, albuterol sulfate, and micronized budesonide/micronized formoterol fumarate dihydrate. Physical examination was unremarkable, except for cardiopulmonary distress. Laboratory tests showed leucocytosis. His chest X-ray revealed infiltrates and interstitial edema in the lower lung fields. A PCR test for SARS-CoV-2 was positive. COVID-19 pneumonia was diagnosed, and the patient was admitted to the hospital, where he was treated with acetaminophen, amoxicillin, dexamethasone, and supplemental oxygen. The patient remained stable and was discharged from the hospital the following day. He was free of all symptoms after 21 days. Conclusions:This case of a 75-year-old man who presented with mild COVID-19 supports the findings from other reports of improvement in clinical outcomes for some patients with asthma who received treatment with mepolizumab.

show abstract

Section: Discussionsupporting

confidence: 86%